1st Quarter - Report
LMH STRATEGIC SOLUTIONS for ALKERMES, INC.
Client
Income
$60,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SOPHIE KHANAHMADI | Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions |
| ALANNA TEMME | Legislative Director, U.S. Representative Jon Porter |
| MAXIMILIAN WALTER New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.